local_hospital

Sygehus Soenderjylland Soenderborg

Address
lock Available on a paid plan

Oncology and Cancer Care

At Sygehus Soenderjylland Soenderborg, a major share of the research focuses on breast cancer and lung cancer, with additional work in colon cancer and triple-negative breast cancer. These studies are designed to compare newer treatment options with established care, improve survival outcomes, and refine how response to therapy is assessed.

  • Testing new treatment combinations for advanced and early-stage breast cancer
  • Evaluating therapies for non-small cell lung cancer and small cell lung cancer
  • Improving disease-free survival and recurrence prevention in colon cancer

The oncology portfolio reflects a strong interest in both targeted therapy and treatment effectiveness, especially for patients with higher-risk disease.

Cardiovascular Research

Clinical trials at this site also cover a broad range of cardiovascular diseases, including heart failure, myocardial infarction, atherosclerotic cardiovascular disease, and hypertrophic cardiomyopathy. The research aims to find better ways to reduce serious heart-related events, ease symptoms, and improve long-term outcomes.

  • Studying treatments for heart failure, including forms linked to reduced or preserved ejection fraction
  • Evaluating prevention strategies after myocardial infarction and in high-risk cardiovascular disease
  • Assessing therapies for cardiomyopathy and related functional limitations

This activity highlights a strong focus on cardiac care and on finding practical options that may improve everyday health for patients with chronic heart conditions.

Orthopedics, Pain, and Bone Health

Given the site’s Department of orthopedics, it is notable that several studies address hip fractures, osteoporosis, and pain control around surgery. These trials are aimed at improving comfort, recovery, and fracture prevention in older adults and other vulnerable patient groups.

  • Testing pain relief approaches in hip fracture surgery
  • Studying whether stopping long-term bone treatment affects fracture risk
  • Exploring better support for patients with osteoporosis

The orthopedic research at Sygehus Soenderjylland Soenderborg combines symptom relief with efforts to improve mobility and reduce future injury.

Neurology, Stroke, and Autoimmune Disease

Another important area is nervous system disease, especially multiple sclerosis and acute ischemic stroke. The studies in this field aim to improve treatment effectiveness, support faster recovery, and compare established therapies in real-world clinical settings.

  • Comparing treatment options for active multiple sclerosis
  • Investigating better acute care for stroke patients
  • Assessing early neurological improvement after emergency treatment

This research supports efforts to strengthen both neurological treatment and timely decision-making in urgent care.

Infectious Disease and Hospital Medicine

The site also contributes to studies in bacterial infections and acute hospital care, including Staphylococcus aureus bacteremia, complicated urinary tract infections, and critically ill patients admitted to intensive care. These trials are focused on improving infection control, treatment success, and care quality in the hospital setting.

  • Comparing antibiotic strategies for bloodstream infection and urinary tract infection
  • Evaluating care approaches for patients with severe acute illness
  • Studying ways to improve outcomes in intensive care

Overall, this work supports safer and more effective hospital-based treatment for patients with serious infections and critical illness.

Metabolic, Digestive, and Respiratory Conditions

Research at the site extends into metabolic disease, digestive system disease, and respiratory disease, with studies in obesity, gastroesophageal reflux disease, and non-small cell lung cancer. The purpose is to improve symptom control, reduce complications, and evaluate new treatment approaches across several common chronic conditions.

  • Exploring therapies for obesity and related cardiovascular risk
  • Studying treatment options for GERD in infants
  • Assessing new approaches in lung cancer care

This broad portfolio shows an interest in both chronic disease management and targeted treatment evaluation across age groups.

Site Overview

assignment
36
connected trials
corporate_fare
28
sponsors
science
119
IMPs

Activity Indicator

Last 6 months

6
Trials started
+100% vs previous period.
3
Trials started 6–12 months ago
36
Total trials linked
Highly Active
trending_upGrowing+100%
1
2
3
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 14 therapeutic areas and 15 of 119 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 110 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
23
Sponsors (total)
28
Active sponsors
18

Sponsor Network

Top 18 by active trials.

lock +17 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +4 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 111 other sites in Denmark

description
Trial volume
36
Outperforms 85% of sites
public
Therapeutic diversity
14areas
Outperforms 86% of sites
groups
Sponsor diversity
28sponsors
Outperforms 88% of sites

Therapeutic Area Benchmark — Denmark

Select a therapeutic area to compare against other sites in Denmark.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Denmark

Market Share

Country: Denmark

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Sygehus Soenderjylland Soenderborg

lock Showing 1 of 36 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF HospitalizationNovo Nordisk A/SPhase IIIRecruitingApr 2026

IMP list

lock Showing 1 of 119 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab6Unknown2019-12-022025-10-28

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.